People Background Check
Find People:

Kit M Lam, Age 49San Leandro, CA

Get Report
Known as:
Kit K Lam
Related to:
Sally D Ho 32 David M Ho 47

Kit Lam Phones & Addresses

San Leandro, CA

Sunnyvale, CA

San Diego, CA

Alameda, CA

Hayward, CA

Honolulu, HI

Hercules, CA

Show more

Mentions for Kit M Lam

Career records & work history

Medicine Doctors

Kit S. Lam

Specialties:
Medical Oncology
Work:
UC Davis Medical GroupUC Davis Comprehensive Cancer Center
2279 45 St STE 3100, Sacramento, CA 95817
(916) 703-5200 (phone) (916) 703-5265 (fax)
Site
Education:
Medical School
Stanford University School of Medicine
Graduated: 1984
Conditions:
Lung Cancer
Languages:
English, Spanish
Description:
Dr. Lam graduated from the Stanford University School of Medicine in 1984. He works in Sacramento, CA and specializes in Medical Oncology. Dr. Lam is affiliated with UC Davis Medical Center.

Kit Lam resumes & CV records

Resumes

Kit Lam Photo 37

Kit Lam

Location:
United States
Kit Lam Photo 38

Kit Lam

Location:
United States
Kit Lam Photo 39

Kit Lam

Location:
United States
Kit Lam Photo 40

Kit Lam

Location:
San Francisco Bay Area
Industry:
Computer Software
Kit Lam Photo 41

Kit Lam

Location:
San Francisco Bay Area
Industry:
Computer Software
Kit Lam Photo 42

Kit Lam

Location:
San Francisco Bay Area
Industry:
Computer Software

Publications & IP owners

Us Patents

Apolipoprotein Nanodiscs With Telodendrimer

US Patent:
2013016, Jun 27, 2013
Filed:
Dec 19, 2012
Appl. No.:
13/719785
Inventors:
The Regents of The University of California - Oakland CA, US
Wei He - Davis CA, US
Kit S. Lam - Davis CA, US
Paul Henderson - Dublin CA, US
Matt Coleman - Oakland CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 17/02
US Classification:
530359, 435 681
Abstract:
The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R), wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

Llp2A-Bisphosphonate Conjugates For Osteoporosis Treatment

US Patent:
2014005, Feb 27, 2014
Filed:
Jan 19, 2012
Appl. No.:
13/820362
Inventors:
Kit S. Lam - Oakland CA, US
Ruiwu Liu - Oakland CA, US
Wei Yao - Oakland CA, US
Nancy Lane - Oakland CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C07K 5/11
A61K 47/48
US Classification:
424 937, 530330, 514 169, 514 167, 514 168
Abstract:
The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the αβintegrin on mesenchymal stem cells and for the surface of bone.

Methods And Cell Lines For Immortalization And Monoclonal Antibody Production By Antigen-Stimulated B-Lymphocytes

US Patent:
4574116, Mar 4, 1986
Filed:
Jan 13, 1983
Appl. No.:
6/457795
Inventors:
Henry S. Kaplan - Stanford CA
Nelson N. H. Teng - Palo Alto CA
Kit S. Lam - Palo Alto CA
Francisco Calvo-Riera - Leon, ES
Assignee:
The Board of Trustees of the Leland Stanford Jr. University - Stanford CA
International Classification:
C12P 2100
C12N 1500
C12N 1300
C12N 500
US Classification:
435 68
Abstract:
Methods are provided for producing fusion partners which involve employing an immortalized human myeloma cell line sensitive to HAT and having an additional dominant selectable resistance marker and fusing the doubly marked human myeloma cells with a stable immortalized rodent myeloma cell line, desirably previously subjected to substantial chromosome damage, and isolating cells having a substantially complete chromosomal complement of the rodent cell and at least about one chromosome of the human cell having a gene expressing said resistance, thereby being resistant to a selective agent. The resulting heteromyeloma may be fused with high efficiency with human lymphocytes to produce monoclonal antibodies. The cell lines designated as A6 and 36 were deposited at the A. T. C. C. on Jan. 11, 1983 and given accession numbers CRL8192 and CRL8193, respectively.

Site-Specific Covalent Chemical Ligation To Monoclonal And Polyclonal Immunoglobulin

US Patent:
2021035, Nov 18, 2021
Filed:
Mar 16, 2020
Appl. No.:
16/820096
Inventors:
- Oakland CA, US
Chun FENG - Oakland CA, US
Gaurav BHARDWAJ - Oakland CA, US
Siddarth CHANDRASEKARAN - Oakland CA, US
Kit S. Lam - Oakland CA, US
International Classification:
A61K 47/65
C07D 403/12
C07D 495/04
A61K 47/68
Abstract:
Methods and compositions are described herein for covalently linking an antibody to a molecular payload. Compositions are described herein containing an antibody covalently linked to a molecular payload.

Proteoglycan Mimetics For Enhanced Wound Healing, Angiogenesis, And Vascular Repair

US Patent:
2021009, Apr 1, 2021
Filed:
Oct 2, 2020
Appl. No.:
17/062300
Inventors:
- Oakland CA, US
- West Lafayette IN, US
Jenny B. Lin - Oakland CA, US
Kit S. Lam - Davis CA, US
Ruiwu Liu - Oakland CA, US
Dake Hao - Oakland CA, US
Aijun Wang - Sacramento CA, US
Assignee:
The Regents of the University of California - Oakland CA
Purdue Research Foundation - West Lafayette IN
International Classification:
A61K 47/61
A61K 47/64
A61K 47/60
C07K 7/06
C07K 7/08
A61P 9/00
Abstract:
The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

Site-Specific Covalent Chemical Ligation To Monoclonal And Polyclonal Immunoglobulin

US Patent:
2018014, May 24, 2018
Filed:
Oct 6, 2017
Appl. No.:
15/727490
Inventors:
- Oakland CA, US
Chun FENG - Oakland CA, US
Gaurav BHARDWAJ - Oakland CA, US
Siddarth CHANDRASEKARAN - Oakland CA, US
Kit S. LAM - Oakland CA, US
International Classification:
A61K 47/65
C07D 495/04
C07D 403/12
A61K 47/68
Abstract:
Methods and compositions are described herein for covalently linking an antibody to a molecular payload. Compositions are described herein containing an antibody covalently linked to a molecular payload.

Nanoporphyrin Telodendrimers For Treatment Of Vascular Abnormalities

US Patent:
2018007, Mar 22, 2018
Filed:
Apr 22, 2016
Appl. No.:
15/568749
Inventors:
- Oakland CA, US
David SAHAR - Oakland CA, US
Yuanpei LI - Oakland CA, US
Kit S. LAM - Oakland CA, US
International Classification:
A61K 47/60
A61K 41/00
A61K 31/475
A61K 9/00
A61K 31/5377
A61K 47/54
A61N 5/06
Abstract:
Methods and compositions are provided for treating a vascular abnormality.

Possible Relatives

Cyrus E Lam  De D Lam  Dai V Lam  Daisy C Lam  Debbie A Lam  Dallas R Lam  Dan L Lam  Kit M Klein  Kit H Kwan  Kit Y Lau 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.